background: Increased prevalence of abnormal aminotransferase levels and/or ultrasonographic evidence of hepatic steatosis (HS) have been found in women with polycystic ovary syndrome (PCOS). However, factors associated with non-alcoholic fatty liver disease (NAFLD) in PCOS are still under investigation. The aim of this case-control study was to investigate the presence of NAFLD and to assess factors associated with this condition in PCOS patients.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is an increasingly recognized disorder characterized by fat accumulation in the liver, histologically identical to alcoholic liver disease, in patients without significant alcohol consumption, after exclusion of nutritional disorders, drugs and diseases known to cause secondary fatty liver disease (Angulo, 2002) . There is a wide spectrum of liver damage ranging from simple steatosis to cirrhosis. Simple steatosis is considered a benign condition but progression to non-alcoholic steatohepatitis (NASH) and to advanced fibrosis or cirrhosis has been detected in a subset of patients (Matteoni et al., 1999; Angulo, 2002) . The clinical relevance of NAFLD is related to (i) its high prevalence (10-30%) (Angulo, 2002; Bedogni et al., 2005) in the general population and (ii) possible evolution to end-stage liver disease, and rarely to hepatocellular carcinoma (Bugianesi and Leone, 2002) . As NAFLD prevalence is markedly increased in obesity, in type 2 diabetes mellitus and in dyslipidemia (Angulo, 2002 ) the role of insulin resistance in the pathogenesis of NAFLD has been studied and a strong association has been shown between the two entities (Marchesini et al., 1999; Bugianesi et al., 2005) . However, the underlying mechanisms linking NAFLD and insulin resistance are still under investigation (Utzschneider and Kahn, 2006) . Existing data support that NAFLD is the hepatic component of metabolic syndrome (Marchesini et al., 2001) .
Polycystic ovary syndrome (PCOS), affecting 5-8% of premenopausal women (Knochenhauer et al., 1998; Diamanti-Kandarakis et al., 1999) , is characterized by hyperandrogenism and ovulatory dysfunction. Hyperandrogenism is usually clinically expressed as hirsutism, acne and/or androgenic alopecia, and ovulatory dysfunction as oligomenorrhea or amenorrhea and subfertility (Norman et al., 2007) . Other diseases causing the same symptoms have to be excluded before considering the diagnosis of PCOS. Insulin resistance has been shown to be an essential feature of the syndrome affecting both obese and lean patients, long after its first description (Dunaif et al., 1989) . Subsequent investigation of metabolic abnormalities in PCOS revealed an increased prevalence of impaired glucose tolerance and diabetes mellitus (Legro et al., 1999) , abdominal adiposity (Carmina et al., 2007) and dyslipidemia (Legro et al., 2001) , implicating that these patients are at increased risk for metabolic syndrome (Essah and Nestler, 2006) . Moreover, altered endothelial function and vascular morphology have been shown in these patients (Paradisi et al., 2001; Vryonidou et al., 2005) .
The first evidence for the association of NAFLD and PCOS was reported in 2005, when biopsy-documented NASH was described in a young patient with PCOS (Brown et al., 2005) . It was then suggested that NALFD might occur in some patients with PCOS given that insulin resistance is a common feature in both NAFLD and PCOS and both disorders are linked with metabolic syndrome. A few studies (Schwimmer et al., 2005; Setji et al., 2006; Cerda et al., 2007; Gambarin-Gelwan et al., 2007) , all retrospective except one (Cerda et al., 2007) , followed and showed an increased prevalence (15 -55%) of NAFLD in women with PCOS based on abnormal aminotransferase levels and/or ultrasonographic evidence of hepatic steatosis. Moreover, six young patients with PCOS, all obese, have been reported with biopsy-documented NASH (Setji et al., 2006) . At variance with previous data, a recent small prospective study did not show evidence of NAFLD in young lean PCOS patients assessed both by imaging methods [ultrasonography and computed tomography (CT) of the liver] and by enzyme levels (Markou et al., 2009) . Therefore, factors associated with NAFLD in PCOS need to be clarified in order to identify which patients are at risk for developing NAFLD. Moreover, there are no data about the potential contribution of hyperandrogenism to NAFLD.
In the present study premenopausal women with PCOS were evaluated with abdominal ultrasonography and biochemical testing in order to investigate the presence of NAFLD and to assess metabolic and hormonal factors associated with NAFLD in PCOS. 2 )] were also recruited from those attending our outpatient endocrine clinic for obesity or thyroid disorders in addition to volunteers from the hospital's medical and paramedical staff. Controls had normal menses and no clinical signs of hyperandrogenism. Patients and controls were all Caucasian. Exclusion criteria for both patients and controls were (i) report of alcohol consumption more than 20 g alcohol per day (ii) history of known liver disease including viral, autoimmune, genetic and drug induced liver disease and (iii) use of any medication in the last three months preceding the entry to the study. No PCOS patient had diabetes mellitus or hypertension.
Materials and Methods

Patients
Study protocol
Patients and controls were studied in the early follicular phase. They underwent a clinical examination, during which anthropometric measurements (weight, height, waist and hip circumference) and blood pressure were recorded, a biochemical evaluation and a liver and a pelvic ultrasound. Biochemical evaluation consisted of hematological profile, creatinine, fasting glucose and insulin, serum aspartate (AST) and alanine aminotransferases (ALT), g-glutamyltransaminase (gGT), total and direct bilirubin, alkaline phosphatase (ALP), C-reactive protein (CRP), hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies, antinuclear antibodies, ferritin, serum iron, total cholesterol, low-density lipid (LDL) cholesterol, high-density lipid (HDL) cholesterol, triglycerides, FSH, LH, total testosterone (TT), D 4 -androstendione (D 4 A), dehydroepiandrosterone sulphate (DHEA-S) and sex hormone binding globulin (SHBG). Abnormal aminotransferase levels were defined as values exceeding the upper normal level in our hospital's laboratory (ALT and/or AST !40 IU/l). Free androgen index (FAI) was calculated as TT (nmol/l) Â 100/SHBG (nmol/l). Insulin resistance was assessed by homeostasis model assessment of insulin resistance (HOMA-IR) which was calculated as fasting insulin (m U/ml) Â fasting glucose (mmol/l)/22.5 (Bonora et al., 2000) . Metabolic syndrome was diagnosed in patients and controls based on the presence of three or more of the following findings: (i) waist circumference (WC) .88 cm (ii) serum triglycerides !1.69 mmol/l (iii) HDL cholesterol ,1.29 mmol/l (iv) serum glucose levels !6.05 nmol/l according to ATP III criteria (NCEP/ATP III, 2001). Blood pressure !135/ 85 mmHg was not used as a criterion, as all patients and controls were normotensive.
The study protocol was approved by the Ethics Committee of our hospital and informed consent was obtained from all patients and controls.
Assays
All hormone assays were performed with commercially available kits. Serum FSH, LH and testosterone were measured by electrochemiluminescence immunoassay (ECLIA; Roche Diagnostics GmbH, Mannheim, Germany) on an autoanalyzer (Modular Analytics E170). The assay's lower detection limit for serum testosterone was 0.069 nmol/l and intra-and inter-assay coefficients of variation were 2.7 and 5.6%, respectively. Serum SHBG and insulin were measured by immunoradiometric assay (IRMA; Biosource Europe SA, Nivelles, Belgium). The assay's lower detection limit for SHBG was 0.26 nmol/l and for insulin 1.0 mIU/l and intra-and inter-assay coefficients of variation were for SHBG 3.3 and 2.2% and for insulin 2.97 and 6.5%, respectively. Serum D 4 A and DHEA-S were measured by radioimmunoassay (RIA; Diagnostic Systems Laboratories Inc., Texas, USA and Biosource Europe SA, Nivelles, Belgium, respectively). Hematological profile, glucose, creatinine, liver function tests, lipid profile, serum iron, ferritin were determined by routine laboratory methods. ALT and AST were measured by an IFCC method without P-5 0 -P on an autoanalyzer (Konelab 60i).
Ultrasonography
Ultrasonography was performed by the same radiologist who was unaware of the subjects' medical histories and laboratory findings. A highresolution B-mode scanner of General Electric Logiq 5, with a 3.5 MHz convex-array probe was used. All ultrasonographic images were stored as photocopies.
(i) Abdominal ultrasound: the following ultrasonographic findings were evaluated: ultrasonographic contrast between hepatic and right renal parenchyma (hepatorenal echo contrast), abnormally intense highlevel echoes arising from the hepatic parenchyma, echo penetration into the deep portion of the liver, intrahepatic vessel blurring and abnormal visualization of the diaphragm. Absence of hepatic steatosis was defined as equal or slightly greater echogenicity of hepatic parenchyma to that of the renal cortex with clear visualization of the intrahepatic vessels and the diaphragm. Mild hepatic steatosis was defined as a slight diffuse increase in fine echoes in the hepatic parenchyma with clear visualization of the intrahepatic vessels and the diaphragm. Moderate hepatic steatosis was defined as a moderate diffuse increase in fine echoes in the hepatic parenchyma with slightly impaired visualization of the intrahepatic vessels and the diaphragm. Severe hepatic steatosis was defined as a marked increase in fine echoes in the hepatic parenchyma with poor or absence of visualization of the intrahepatic vessels, the diaphragm and the posterior right hepatic lobe (Saadeh et al., 2002) . (ii) Pelvic ultrasound: transvaginal pelvic ultrasound was performed in the majority of patients and controls (those who refused and those who had had no previous sexual relations were examined transabdominally). Polycystic ovarian morphology was defined as presence of 12 or more follicles measuring 2 -9 mm in diameter and/or ovarian volume.10 ml of at least one ovary (Balen et al., 2003) .
Statistical analysis
Results for continuous variables are presented as mean + SD and for categorical variables as absolute number and as percentage in parentheses. Differences in variables between groups (PCOS patients and controls) and subgroups were tested with Mann -Whitney test and x 2 test, as appropriate. Univariate logistic regression analysis was applied to evaluate the effect of age, BMI, WC, HOMA-IR, total cholesterol, HDL cholesterol, triglycerides, TT, SHBG, FAI, D 4 A and DHEA-S, as well as PCOS diagnosis (used as independent variables) on the presence of hepatic steatosis (used as the dependent variable) for all subjects. Since older age, increased BMI and WC are known factors associated with the presence of hepatic steatosis, multivariate regression analysis was used to control for confounding. Multivariate models were performed for each of the independent variables that were significantly related to hepatic steatosis by univariate regression: HOMA-IR, HDL cholesterol, SHBG, FAI and PCOS, after adjusting for age, BMI and WC. All statistical analyses were performed using the Statistical Package for Social Sciences (SPSS 13.0, Inc., Chicago, IL, USA). A P , 0.05 was considered statistically significant.
Results
Laboratory evaluation
Clinical and laboratory characteristics of 57 patients with PCOS and 60 age and weight matched healthy control women are shown in Table I . Patients with PCOS had a more pronounced abdominal adiposity (P ¼ 0.013) estimated by W/H ratio, higher levels (P , 0.001) of all measured androgens (TT, DHEAS and D 4 A) and FAI (,0.001), higher ALT (P ¼ 0.007) and g-GT levels (P ¼ 0.009) and lower SHBG levels (P , 0.001) and HDL cholesterol (P ¼ 0.004) than controls. Fasting glucose levels and triglycerides levels tended to be higher (P ¼ 0.055 and 0.07, respectively) in PCOS patients compared with controls, whereas insulin resistance estimated by HOMA-IR and insulin fasting levels were similar in both groups. Total and direct bilirubin, ferritin, serum iron and CRP values were normal in all women. The frequency of metabolic syndrome was not significantly different between patients and controls. Abnormal aminotransferase levels were detected in 13 PCOS patients (9 obese, 3 overweight and 1 lean) and two controls (P , 0.01) (Fig. 1) . Abnormal ALP levels (.270 IU/l) were detected in an overweight PCOS patient (combined with abnormal aminotransferase levels) and abnormal g-GT (.50 IU/l) in an obese PCOS patient (combined with abnormal aminotransferase levels) and two controls (isolated abnormality). All controls with abnormal liver biochemistry were obese.
Ultrasonography
Hepatic steatosis was detected in 21 patients with PCOS (17 obese, 2 overweight and 2 lean) and in 12 controls (10 obese and 2 overweight) (P , 0.05) (Fig. 1) . Abnormal aminotransferase levels were detected in 11/21 patients and 2/12 controls of all women with hepatic steatosis (21 þ 12), whereas hepatic steatosis was detected in 11/13 patients and 2/2 controls of all women with abnormal aminotransferase levels (13 þ 2). All patients and controls presenting metabolic syndrome had hepatic steatosis. Polycystic ovarian morphology was detected in 47 patients with PCOS and in 10 controls.
Subgroup analysis
PCOS patients and controls with hepatic steatosis PCOS patients with hepatic steatosis had a higher W/H ratio (P , 0.05), higher ALT and AST (P , 0.05 and P , 0.05, respectively), FAI (P , 0.001), TT (P , 0.001) and D 4 A (P , 0.001) levels and lower HDL cholesterol (P , 0.05) and SHBG (P , 0.001) levels than controls with hepatic steatosis (Table II) .
PCOS patients with and without hepatic steatosis
PCOS patients with hepatic steatosis were older (P ¼ 0.032), had higher BMI (P , 0.001), W/H ratio (P , 0.001), HOMA-IR (P , 0.001), fasting insulin (P , 0.001), FAI (P , 0.001), total cholesterol (P ¼ 0.038), triglycerides (P ¼ 0.004), LDL cholesterol (P ¼ 0.035), ALT (P , 0.001), AST (P , 0.001), g-GT levels (P , 0.001) and lower HDL cholesterol (P , 0.001) and SHBG levels (P , 0.001) than patients without hepatic steatosis. All patients presenting metabolic syndrome had hepatic steatosis (Table II) . There was no difference in the presence of polycystic ovarian morphology between the two subgroups.
Controls with and without hepatic steatosis
Controls with hepatic steatosis tended to be older (P ¼ 0.06), had higher BMI (P , 0.001), W/H ratio (P ¼ 0.03), HOMA-IR (P , 0.001), fasting insulin (P , 0.001) and glucose (P ¼ 0.037), FAI (P ¼ 0.019), total cholesterol (P , 0.001), LDL cholesterol (P ¼ 0.003), triglycerides (P , 0.001) and g-GT levels (P , 0.001) and lower D 4 A (P ¼ 0.032), HDL cholesterol (P ¼ 0.026) and SHBG levels (P ¼ 0.002) than controls without hepatic steatosis. All controls presenting metabolic syndrome had hepatic steatosis (Table II) .
PCOS patients with and without abnormal aminotransferase levels PCOS patients with abnormal aminotransferase levels had higher BMI (P , 0.001), HOMA-IR (P ¼ 0.003), FAI (P ¼ 0.001) and fasting insulin levels (P ¼ 0.002) and lower HDL cholesterol (P ¼ 0.017) and SHBG levels (P ¼ 0.001) than patients with normal aminotransferase levels. W/H ratio and fasting glucose levels tended to be higher in PCOS patients with abnormal aminotransferase levels (P ¼ 0.057 and P ¼ 0.056, respectively) (Table III) .
Comparisons between the following subgroups (i) PCOS patients and controls with abnormal aminotransferase levels and (ii) 
Hyperandrogenism and NAFLD in PCOS patients
with and without abnormal aminotransferase levels could not be performed because only two controls had abnormal aminotransferase levels.
Logistic regression analysis
Univariate regression analysis showed that older age, increased BMI, WC, HOMA-IR and FAI, decreased HDL cholesterol and SHBG levels and PCOS diagnosis were factors significantly related to the presence of hepatic steatosis (Table IV) , whereas total cholesterol, triglycerides, TT, D 4 A and DHEA-S levels were not related. Multivariate regression models showed that increased HOMA-IR and FAI, decreased HDL cholesterol and SHBG levels and PCOS diagnosis remained significantly related to the presence of hepatic steatosis after adjustment for age, BMI and WC (Table V) .
Discussion
In the present prospective study, increased prevalence of serum aminotransferase levels and of fatty liver infiltration was detected in premenopausal women with PCOS compared with healthy control women, showing that NAFLD is common in these patients. Serum aminotransferase levels have been widely used as indicative biochemical findings of NAFLD after excluding other potential liver diseases in patients with no or minimal alcohol consumption. Increased prevalence of abnormal aminotransferase levels has been recently reported in patients with PCOS ranging from 15 to 39% depending on the cut-off levels used to define abnormal findings (Schwimmer et al., 2005; Setji et al., 2006; Cerda et al., 2007; Gambarin-Gelwan et al., 2007; Preiss et al., 2008) . In agreement with existing data abnormal aminotransferase levels were detected in 22.8% of our patients using a cut-off ALT or AST levels !40 U/l. Setji et al. used a cut-off level of ALT or AST . 60 U/l, which were the upper normal limits in their laboratory, whereas Cerda et al. used a cut-off ALT level .25 U/l according to normal values for healthy Chilean women. It has been proposed that upper normal level for ALT in women should be even lower (19 U/l) (Prati et al., 2002) and if this very low cut-off level is applied, then the prevalence increases dramatically to 84% in Setji et al. study and 49% in our study. The differences in prevalence using the same cut-off level in the two studies should be attributed to the fact that all PCOS patients were obese in Setji et al. study, increasing the likelihood of NAFLD, as obesity is an independent risk factor for NAFLD (Angulo, 2002; Bedogni et al., 2005) , whereas in our study approximately only one third of PCOS patients were obese. However, elevations of aminotransferase levels can be used as a crude estimate of the presence of NAFLD given that more than half of the patients with fatty liver do not have laboratory abnormalities (Angulo, 2002) .
Ultrasonography is the most widely used imaging method for detecting fatty liver infiltration, as it has been shown to have an acceptable level of sensitivity for detecting fatty liver (sensitivity 80% in the presence of !30% of fatty infiltration), a short examination time and a low cost. In agreement with previous studies showing an increased prevalence of hepatic steatosis by ultrasound examination in PCOS patients (Cerda et al., 2007; Gambarin-Gelwan et al., 2007) we found that 36.8% of our PCOS patients had hepatic steatosis. However, this percentage was lower compared with the aforementioned studies, in which it reached 55 and 41.5%, respectively. These differences could be possibly attributed to ethnic differences. In Gambarin-Gelwan et al. study patients were of several ethnicities, Results for continuous variables are expressed as mean + SD. P-value is for unpaired t-test in Cerda et al. study the majority of patients and controls were Hispanics, as this ethnicity is predominant in Chile, whereas in our study all patients and controls were Caucasian. The influence of medication is also a concern, as 36% of PCOS patients in Gambarin-Gelwan et al. study were receiving oral contraceptives at the time of abdominal ultrasonography, although a lower prevalence of hepatic steatosis was reported in patients treated with oral contraceptives. The presence of NAFLD in PCOS patients may occur irrespectively of obesity as reported in Gambarin-Gelwan et al. study, where 39% of PCOS patients with ultrasonographic evidence of hepatic steatosis, were lean. This is in accordance with data showing the presence of biopsy proven NAFLD in lean, insulin resistant patients (Chitturi et al., 2002; Bugianesi et al., 2005) . At variance Markou et al. did not detect NAFLD in a small group of young, lean PCOS patients either biochemically or by imaging techniques (ultrasound and CT). These differences could be attributed to age differences given the fact that the prevalence of NAFLD increases with age (Angulo, 2002) , as in Gambarin-Gelwan et al. study patients had a median age of 31.4 years whilst in Markou et al. study a mean age of 25.1 years. In our study two lean PCOS patients, aged 27 and 30 years old had liver steatosis on ultrasonography and a third, aged 24 years old had increased ALT levels. On the basis of the above findings, it should be expected that the younger and leaner a PCOS patient is, the less probable is for NAFLD to be present.
In our cohort, subgroup analysis between PCOS patients with and without hepatic steatosis, as well as controls with and without hepatic steatosis showed that age, obesity, abdominal adiposity, insulin resistance and abnormal lipid profile were factors associated with the presence of NAFLD, in agreement with the literature (Marchesini et al., 1999 (Marchesini et al., , 2001 Angulo, 2002; Bugianesi et al., 2005; Utzschneider and Kahn, 2006) . Moreover, it was shown for the first time that decreased SHBG and increased FAI values are also associated with the presence of NAFLD both in patients and controls. Low SHBG levels, considered a marker of insulin resistance and also a marker of hyperandrogenism, have been associated with metabolic syndrome and its components in pre-menopausal (Korhonen et al., 2003) and post-menopausal women (Weinberg et al., 2006) . However, there are no data in either pre-or post-menopausal women with NAFLD. The association of decreased SHBG levels with NAFLD most probably reflects the known abnormalities associated with NAFLD that influence SHBG secretion by the liver, such as obesity, central adiposity and insulin resistance. However, this association remained after adjustment for BMI and WC, suggesting that it is independent of obesity and abdominal adiposity. Hyperandrogenism is an additional factor that reduces SHBG secretion in PCOS patients with NAFLD and this explains the even lower SHBG levels found in PCOS patients with hepatic steatosis compared with controls with hepatic steatosis, being similarly obese and insulin resistant.
Increased androgen bioavailability, estimated by FAI, was an expected finding due to the decreased levels of SHBG, both in PCOS patients and controls with hepatic steatosis. However, this finding is clinically significant only in PCOS patients who have increased total androgen levels. Thus hyperandrogenism can be implicated with the observed increased prevalence of NAFLD in PCOS patients. Association of abnormal ALT levels with hirsutism in PCOS patients with NAFLD is the only existing data in the literature (Schwimmer et al., 2005) . The significance of increased androgen bioavailability in the pathogenesis of NAFLD in women needs to be addressed in further studies, since this is a cross-sectional study and causality of the association cannot be demonstrated. Other factors possibly contributing to the observed increased prevalence of NAFLD in PCOS patients are more pronounced abdominal adiposity and more severe dyslipidemia since subgroup analysis between PCOS patients and controls with hepatic steatosis showed that they differed in W/H ratio and HDL cholesterol levels.
All PCOS patients and controls with metabolic syndrome had evidence of hepatic steatosis on ultrasound. This finding is in accordance with data showing that NAFLD should be considered as a feature of metabolic syndrome (Marchesini et al., 1999 (Marchesini et al., , 2001 Angulo, 2002; Bugianesi et al., 2005) and emphasizes the need of evaluation for the presence of NAFLD in premenopausal women with metabolic syndrome irrespectively of PCOS diagnosis.
It should be noted that both abnormal aminotransferase levels and ultrasonographic evidence of hepatic steatosis are indicative findings of NAFLD, the gold standard for the diagnosis being biopsy. Even the most accurate non-invasive method for the assessment of hepatic steatosis, which is proton magnetic resonance spectroscopy (Szczepaniac et al., 2005) cannot detect inflammation and fibrosis. Moreover, as aforementioned, many patients with fatty liver do not have laboratory abnormalities, and ultrasonography does not reliably detect hepatic steatosis below 30% of fatty infiltration, thus the true prevalence of NAFLD both in PCOS patients and controls of our study is most probably underestimated. However, both biochemical testing and ultrasonography are acceptable screening methods for this entity. Another limitation of the study is the relatively small number of patients and controls. Strengths of the study include the prospective collection of data, comparison of patients with age-and weightmatched controls and a homogenous group of subjects concerning race and ethnicity.
Although the natural history of NAFLD remains unclear and hepatic steatosis seems to be a relatively benign condition in the majority of patients, it is a potentially progressive liver disease as existing data indicate that most cases of 'cryptogenic' cirrhosis probably represent late stage of this entity (Angulo, 2002; Liu and Kowdly, 2006) . Steatosis, steatohepatitis and possibly fibrosis seem to be reversible, since lifestyle modifications including diet, weight loss and exercise, either alone or in combination with pharmacologic therapy have been shown to have beneficial effects in patients with NASH (Angulo, 2002) included PCOS patients, with improvement of liver histology (Brown et al., 2005) and normalization of aminotransferase levels (Setji et al., 2006; Preiss et al., 2008) . Thus, early detection of NAFLD in PCOS patients is important because intervention at an early stage may decrease or even eliminate the possibility of disease progression. Further larger studies examining NAFLD in PCOS patients are needed to determine the most appropriate screening methods and the most effective interventions.
In conclusion, the current study provides strong evidence that NAFLD is common in PCOS patients and increased androgen bioavailability may be implicated, since increased FAI values are associated with the presence of hepatic steatosis, in combination with metabolic abnormalities. Therefore, assessment of aminotransferase levels and evaluation of fatty liver infiltration by ultrasound is proposed, especially in PCOS patients with metabolic syndrome for early diagnosis of NAFLD.
